Clinical and Translational Allergy最新文献

{"title":"Aeroallergen sensitivity patterns in Gulf countries: A systematic review","authors":"Tahira Khurram,&nbsp;Ghalia Missous,&nbsp;Nicholas van Panhuys,&nbsp;Mohammed Yousuf Karim","doi":"10.1002/clt2.70033","DOIUrl":"https://doi.org/10.1002/clt2.70033","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Successful management of allergic diseases necessitates accurate diagnosis, implementation of appropriate allergen avoidance techniques, and medical therapies. However, data availability regarding aeroallergens in the Gulf Cooperation Council (GCC) countries is limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a systematic review of studies conducted in Gulf countries on individuals diagnosed with or tested for aeroallergen sensitivities, focusing on prevalence and respiratory health impacts. The search strategy followed the PRISMA guidelines and was conducted across PubMed, Scopus, Web of Science, and Google Scholar from inception to November 12, 2023.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 27 studies, both adult and pediatric, were included in this systematic review. Aeroallergen sensitization was assessed using skin prick testing (SPT) in 15 studies; 5 used in vitro methods, 2 employed both, 4 relied on self-reports, and 1 on aerobiological monitoring. Sensitization rates varied considerably, influenced by factors such as age, demographics, and location. Sensitization was noted to allergens shared with Western populations, and to those native to the region for example, house dust mite sensitization ranged from 15% to 78%, Salsola from 13% to 78%. Up to 65.1% of allergen-positive individuals demonstrated polysensitization. Sensitization patterns differed between indigenous populations and expatriates, with local allergens being more prevalent among natives. Sensitization rates were lower in younger children but increased with age.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our systematic review highlights the crucial importance of providing allergen-sensitivity information that is specifically tailored to the local environment. This tailored approach can improve clinical diagnosis, enable appropriate allergen avoidance and immunotherapy strategies, and result in potential cost savings.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 2","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70033","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143455883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of repeated drug desensitisation on quality of life in drug hypersensitivity","authors":"Begum Gorgulu Akin,&nbsp;Secil Kepil Ozdemir,&nbsp;Beyza Doganay Erdogan,&nbsp;Asli Gelincik,&nbsp;Ozlem Goksel,&nbsp;Adile Berna Dursun,&nbsp;Sacide Rana Isık,&nbsp;Semra Demir,&nbsp;Hatice Serpil Akten,&nbsp;Sevim Bavbek","doi":"10.1002/clt2.70029","DOIUrl":"https://doi.org/10.1002/clt2.70029","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Measurement of disease-specific quality of life (QOL) is crucial in evaluating the effects of disease and response to treatment. Patients' efforts to avoid the responsible medication can have a negative impact on the QOL of patients with drug hypersensitivity reactions (DHRs). The Drug Hypersensitivity QOL Questionnaire (DrHy-Q) is the only specific tool measuring disease specific QOL in patients with DHRs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To evaluate the effect of repeated drug desensitisation on disease-specific QOL using the Turkish version of DrHy-Q in a prospective multicentre study.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients scheduled to undergo repeated desensitisations with the same drug were included in the study. Baseline DrHy-Q scores were recorded for each patient prior to the commencement of the desensitisation procedure. DrHy-Q scores were then calculated following each desensitisation procedure.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The study included 111 patients with two or more desensitisations (age mean ± SD, years: 53.87 ± 11.36, F/M:94/17). The drugs most implicated in DHRs were chemotherapeutics (91 of 111 patients, 82%) followed by biologicals (16 of 111 patients, 14.4%). Before the desensitisation process, the median (min–max) pre-DrHy-Q score was 39 (16–74). The median (min–max) DrHy-Q scores after the first three desensitisation were 35 (19–69), 34 (15–68) and 35 (15–64), respectively. There was a statistically significant improvement in DrHy-Q scores after the first three desensitisation in comparison with baseline.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The health-related disease-specific QOL of patients with hypersensitivity to drugs significantly improved after the first three, but not after subsequent drug desensitisations, as compared to baseline.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 2","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70029","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143431715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extracellular vesicle as biomarkers in NSAID-exacerbated respiratory disease","authors":"Isaac Kirubakaran Sundar","doi":"10.1002/clt2.70028","DOIUrl":"https://doi.org/10.1002/clt2.70028","url":null,"abstract":"&lt;p&gt;We found the recent Allergy article titled “Extracellular vesicle miRNAs drive aberrant macrophage responses in NSAID-exacerbated respiratory disease” fascinating. We commend the authors for their exciting research into the role of extracellular vesicle (EV) miRNAs in mediating aberrant macrophage responses in NSAID-exacerbated respiratory disease (N-ERD).&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; The authors evaluated EVs from sputum and conditioned medium of the nasal polyp or turbinate tissues from patients with chronic rhinosinusitis with nasal polyps (CRSwNP), N-ERD, and healthy controls.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; Small RNA sequencing revealed intriguing and contrasting miRNA profiles in sputum EVs from N-ERD patients compared to previous reports on BAL fluid EVs from asthmatics,&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; and nasal tissue from CRSwNP patients.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; Specifically, let-7 family miRNAs were upregulated while miR-155 was downregulated in N-ERD sputum EVs.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; These distinct miRNA signatures suggest the source of EVs dictates the enrichment of miRNAs in healthy versus N-ERD samples. Additionally, in vitro experiments supported a role for let-7 family miRNAs in promoting M2 macrophage polarization, which limits cytokine responses triggered by EVs in monocyte-derived macrophages (MDM). This implicates aberrant EV miRNA profiles contributing to N-ERD pathogenesis.&lt;/p&gt;&lt;p&gt;The results obtained from small RNA sequencing analysis are interesting, but the authors have not verified their findings through alternative methods or a replication cohort of samples. They have not provided sufficient details about the total EV concentration and EV protein abundance across the three groups (healthy, CRSwNP, and N-ERD) and the sample types analyzed (sputum vs. turbinate tissue/nasal polyp tissue). It is also unclear whether the EV miRNAs identified match previous findings in similar sample types from asthma and IPF.&lt;span&gt;&lt;sup&gt;4, 5&lt;/sup&gt;&lt;/span&gt; Moreover, the use of pooled samples and a relatively small sample size for the RNA-sequencing and interpretation is surprising. To support the RNA-seq data presented here, direct validation of the miRNA signature and associated mRNA targets in the N-ERD groups is necessary. We have pointed out the strengths and weaknesses of this study below. Overall, we advise caution in interpreting these findings until they are validated in a larger sample cohort by the authors and readers.&lt;/p&gt;&lt;p&gt;This study sheds light on the pathogenesis of N-ERD, which is a severe form of asthma. The study analyzed the RNA-seq data from MDM treated with sputum EVs from healthy, CRSwNP, and N-ERD patients, as well as small RNA-seq of sputum and tissue culture supernatant EVs from healthy turbinate or nasal polyp tissue (N-ERD). Although the authors performed a comprehensive analysis of EV miRNA profiling and in vitro experiments using MDM, the identified EV-specific miRNAs (upregulated miR-125a and let-7 family) enriched in N-ERD sp","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 2","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70028","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143404463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of allergen sensitization among asthmatic patients with serum total IgE >1000 IU/mL","authors":"Wanjun Wang,&nbsp;Lulu Wu,&nbsp;Jing Li,&nbsp;Qiurong Hu","doi":"10.1002/clt2.70034","DOIUrl":"https://doi.org/10.1002/clt2.70034","url":null,"abstract":"&lt;p&gt;To the Editor,&lt;/p&gt;&lt;p&gt;Allergen sensitization occurs in most patients with asthma. Our previous article had demonstrated that house dust mite remained the most important allergen in Chinese individuals with asthma.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; A raised serum IgE against Aspergillus antigens usually occurred in bronchial asthma, especially a value ≥1000 IU/mL was recommended as the serum total IgE (tIgE) cut-off to diagnose Allergic bronchopulmonary aspergillosis (ABPA).&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; Therefore, we aim to describe the prevalence of sensitization to common allergens among asthmatic patients with serum tIgE &gt;1000 IU/mL, the extent to which allergy accounts for these individuals is controversial.&lt;/p&gt;&lt;p&gt;We retrospectively analyzed the laboratory records of 1367 physician-diagnosed asthma patients at the Department of Allergy and Clinical Immunology and Respiratory Medicine, the First Affiliated Hospital of Guangzhou Medical University, who had serum IgE test with a battery of common allergens performed (ImmunoCAP, ThermoFisher) during a 5-year period from January, 2018 through October, 2024. All the patients analyzed had a blood tIgE level &gt;1000 IU/mL. The allergens tested were house dust mite (&lt;i&gt;Dermatophagoides pteronyssimus&lt;/i&gt;), grass pollen mix, food mix, cat, dog, &lt;i&gt;Alternaria alternata&lt;/i&gt;, Aspergillus and &lt;i&gt;Penicillium notatum&lt;/i&gt;. For patients who had multiple measurements performed during the study period, only the first time total serum IgE and specific IgE value were included for analysis. The criteria were excluded for patients with chronic obstructive pulmonary disease, helminth infection, rheumatic disease and tumors. This study was approved by the hospital ethics committee and the need for informed consent was waived.&lt;/p&gt;&lt;p&gt;Our study showed that all the patients were sensitized to at least two allergens and 734 (53.7%) individuals sensitized to more than 5 allergens. Allergic multimorbidities were very commonly found in nearly 98% of all patients’ allergies. Details about the baseline characteristics for patients are in Appendix S1. &lt;i&gt;Dermatophagoides pteronyssimus&lt;/i&gt; (69.4%), &lt;i&gt;Aspergillus fumigatus&lt;/i&gt; (29.7%), and cat (24.9%) were the three most common positive reactions in the tIgE &gt;1000 individuals. Sensitization to inhalant allergens was significantly common (97.8%) as compared with food allergens (2.2%). The respective proportions for grass pollen, dog, &lt;i&gt;A. alternata&lt;/i&gt; and &lt;i&gt;P. notatum&lt;/i&gt; were 7.3%, 10.3%, 17.6% and 4.9% (Figure 1). In addition, a graded effect was observed with the serum tIgE level in these patients increasing with the number of positive allergens (&lt;i&gt;r&lt;/i&gt; = 0.34, &lt;i&gt;p&lt;/i&gt; = 0.047), and the &lt;i&gt;D. pteronyssimus&lt;/i&gt; sIgE level (&lt;i&gt;r&lt;/i&gt; = 0.52, &lt;i&gt;p&lt;/i&gt; = 0.036). However, there was no statistically significant correlation between serum tIgE and Aspergillus sIgE level (Appendix S2).&lt;/p&gt;&lt;p&gt;Our study focused on whether a fungal allergy must be present in asthma with elevated tIgE, and f","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 2","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70034","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143389038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert opinion on gray areas in asthma management: A lesson from the innovative project “revolution in asthma” of the Italian thoracic society (AIPO-ITS)","authors":"Adriano Vaghi,&nbsp;Raffaele Antonelli Incalzi,&nbsp;Simona Barbaglia,&nbsp;Maria Beatrice Bilò,&nbsp;Francesco Bini,&nbsp;Mauro Carone,&nbsp;Lorenzo Cecchi,&nbsp;Alfredo Antonio Chetta,&nbsp;Andrea Claudio Comel,&nbsp;Fausto De Michele,&nbsp;Giuseppe Insalaco,&nbsp;Antonino Musarra,&nbsp;Giovanni Pomponio,&nbsp;Antonio Spanevello,&nbsp;Silvia Tognella,&nbsp;Alessandro Vatrella,&nbsp;Lina Zuccatosta,&nbsp;Claudio Micheletto","doi":"10.1002/clt2.70037","DOIUrl":"https://doi.org/10.1002/clt2.70037","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Despite the availability of numerous guidelines for asthma management, their recommendations are not consistently implemented in clinical practice. This discrepancy between guidelines and real-world practice among Italian healthcare professionals was explored during the “Revolution in Asthma” training program, which identified “gray areas” and barriers preventing clinicians from adopting guideline-based approaches.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aims to analyze the key challenges in asthma management and provide evidence-based solutions to improve adherence to guidelines in clinical practice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A group of experts from the Scientific Committee of the Revolution in Asthma project reviewed the program's findings, focusing on three main areas of asthma management: diagnosis, control, and treatment. The experts summarized clinicians' main needs and questions for each area and provided evidence-based responses and practical recommendations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The study highlights critical challenges in asthma treatment, addressing two key questions: (a) What are the possible uses and indications for short-acting <i>β</i>-agonists in asthma patients? (b) How should asthma treatment be initiated and adjusted based on asthma control? The expert panel developed practical, operational tools to support general practitioners and specialists (pulmonologists and allergists) in optimizing asthma management.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This paper serves as a knowledge co-creation initiative, bridging the gap between clinical guidelines and daily practice. By offering concrete recommendations, it aims to enhance the application of guideline-based asthma management among healthcare professionals.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 2","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70037","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143379908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improvement of glucocorticoid sensitivity and attenuation of pulmonary allergic reactions by exogenous supplementation with betaine in HDM and LPS-induced allergic mouse model","authors":"Qing Wang,&nbsp;Wen He,&nbsp;Yufeng Zhou,&nbsp;Yun Liu,&nbsp;Xiaoling Li,&nbsp;Yingwen Wang,&nbsp;Jiayu Wang,&nbsp;Xiao Han,&nbsp;Xiaobo Zhang","doi":"10.1002/clt2.70039","DOIUrl":"https://doi.org/10.1002/clt2.70039","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Childhood asthma is a heterogeneous disease that exhibits different characteristics and varying severity; however, the metabolite alterations underlying the difference in asthma severity, especially in severe asthma, are not well understood. The aim of this study was to identify the plasma metabolic profile of children with different asthma severity and explore the potential intervention targets in severe asthma and glucocorticoid resistance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Untargeted liquid chromatography mass spectrometry was utilized to analyze plasma metabolites in 54 children with mild-to-moderate asthma, 50 children with severe asthma and 39 healthy controls. Multivariate statistical analyses were used to explore plasma metabolic alterations that were strongly associated with asthma severity. Meanwhile, the severe allergic airway inflammation mice with glucocorticoid resistance were constructed to validate the potential therapeutic capacity of metabolites.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The plasma metabolic profiles of children with mild to moderate asthma and severe asthma exhibited significant alterations. The distinct plasma metabolite shifts were accompanied by functional alterations in lipid metabolism, particularly choline metabolism, glycerophospholipids and sphingolipid metabolism. 11-cis-retinol, LysoPC (20:4 [8Z,11Z,14Z,17Z]), and glycerophosphatidylcholine were associated with exacerbated airway inflammation and lung function. Furthermore, 2-Hydroxyestradiol, LysoPC (18:3 [6Z,9Z,12Z]), zeaxanthin, and betaine were shifted exclusively in the severe asthma group and may serve as potential biomarkers. Subsequent in vivo studies demonstrated that betaine supplementation partially improved glucocorticoid resistance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Overall, children with different asthma severity displayed distinct plasma metabolic patterns. These may contribute to the difference in response to glucocorticoids in childhood asthma and could be potential targets and interventions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 2","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70039","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143370090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of the symptomatic dermographism quality of life questionnaire","authors":"Melba Muñoz,&nbsp;Nicole Schoepke,&nbsp;Sabine Altrichter,&nbsp;Petra Staubach,&nbsp;Clara Geppert-Steidl,&nbsp;Leslie Durner,&nbsp;Jonathan A. Bernstein,&nbsp;Marcus Maurer,&nbsp;Karsten Weller","doi":"10.1002/clt2.70038","DOIUrl":"10.1002/clt2.70038","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Symptomatic Dermographism (SD), also known as “urticaria factitia”, is the most common subtype of chronic inducible urticaria. Affected patients develop itch and strip-shaped wheals that usually last for 30 min after minor stroking, rubbing, or scratching of the skin. The quality of life (QoL) of patients with SD is often strongly affected. However, a QoL instrument to properly assess this impairment is not yet available.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The aim of this study was to develop the first disease-specific patient reported outcome measure|patient reported outcome measures (PROM) to evaluate QoL impairment in SD patients, the Symptomatic Dermographism Quality of Life Questionnaire (SD-QoL).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>SD-QoL was developed following current guidelines for PROM development. We first generated a hypothetical conceptional framework of the SD-QoL, followed by an item generation and an item selection/reduction phase.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>During the item generation phase, 69 potential items of the SD-QoL were generated by applying a combined approach consisting of literature review, expert input as well as semi-structured interviews with affected patients. During the item selection phase, we reduced this long list of items to a final 13-item set by means of impact analysis, inter-item correlation, and additional criteria for item reduction, including an expert review for content (face) validity. Finally, a US-American-English version of the SD-QoL was developed using a structured translation process.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions and Clinical Relevance</h3>\u0000 \u0000 <p>The SD-QoL is the first disease-specific-QoL instrument for SD with a recall period of 7 days that allows the assessment of QoL in SD patients. A subsequent validation study will determine its validity and reliability.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 2","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11785471/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying integrins secreted in serum: Unveiling their correlation with inflammation and asthma—A preliminary study","authors":"Olivia Tellez-Jimenez,&nbsp;Christian Trejo-Jasso,&nbsp;Patricia Ramos-Ramirez,&nbsp;Maryana Tinoco-Cuellar,&nbsp;Diana García-Trejo,&nbsp;Angélica Flores-Flores,&nbsp;Rocío Chapela,&nbsp;José Luis Miguel-Reyes,&nbsp;Blanca Bazán-Perkins","doi":"10.1002/clt2.70023","DOIUrl":"10.1002/clt2.70023","url":null,"abstract":"&lt;p&gt;To the Editor,&lt;/p&gt;&lt;p&gt;Integrins are ubiquitous transmembrane glycoprotein receptors involved in bidirectional signaling across the cell membrane. Integrins are composed of a noncovalent complex that contains an α-subunit and a β-subunit, with 18 and 8 variations, respectively, forming a total of 24 distinct heterodimer.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; The integrin β1 subunit can interact with 12 α subunits, from α1 to α11 and αv. β2 integrins, along with α4β1, are cell adhesion ligands of leukocyte receptors.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; In asthma model, various polypeptides containing both cytosolic and extracellular β1 integrin subunits were detected in airway myocytes and connective tissue, suggesting the secretion of the β1 integrin subunit.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; In the context of asthma patients, studies have documented the presence of soluble extracellular domain of α1 and α2 integrin subunits in serum.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; However, it remains unclear whether cytosolic integrins domains are present in fluids, such as serum, within the context of the asthma.&lt;/p&gt;&lt;p&gt;In patients with asthma (Supporting Information S1: Table S1), the levels of the extracellular domain of α1 and β1 integrin subunits, as well as the intracellular domain of α1 and β2 integrin subunits, were similar to those of healthy subjects (Figure 1). However, in asthma patients, the levels of the extracellular domain of α2 and β2 integrin subunits, as well as the intracellular domain of α2 and β1 integrin, were higher than those observed in healthy subjects (&lt;i&gt;n&lt;/i&gt; = 23, &lt;i&gt;p&lt;/i&gt; &lt; 0.0001). This data is consistent with observations in persistent asthma patients, where an increase in serum soluble α2 integrin (extracellular domain) was observed compared to non-persistent asthma patients, while α1 integrin remained unchanged.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; Interestingly, the expression patterns of integrin β1, α1, and α2 subunits in asthma differed from those observed in scleroderma patients (Supporting Information S1: Figure S1). The integrins α1β1 and α2β1 act as receptors for various types of collagens (I, III, IV, and XIII), each with distinct functions.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; Additionally, integrin fragments have the ability to form heterodimers while retaining identical antigenic and ligand-binding properties as the complete transmembrane integrin.&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; Therefore, the presence of functional soluble integrin heterodimers in serum is feasible.&lt;/p&gt;&lt;p&gt;The changes in the expression of the β1 integrin intracellular domain and both domains of the α2 integrin inversely correlate with FEV1 (Table 1), implying that the severity of asthma may be associated with an upregulation of these integrins. Conversely, the β2 integrin extracellular domain exhibited a direct correlation with FEV1. Supporting this finding, a recent study demonstrated that in asthma patients, this integrin subunit is predominantly released by metalloproteinase-9 (MMP-9) during asthma exacerbatio","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 2","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11781838/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"T2-low severe asthma clinical spectrum and impact: The Greek PHOLLOW cross-sectional study","authors":"Konstantinos Porpodis,&nbsp;Nikolaos Zias,&nbsp;Konstantinos Kostikas,&nbsp;Argyris Tzouvelekis,&nbsp;Michael Makris,&nbsp;George N. Konstantinou,&nbsp;Eleftherios Zervas,&nbsp;Stelios Loukides,&nbsp;Paschalis Steiropoulos,&nbsp;Konstantinos Katsoulis,&nbsp;Anastasios Palamidas,&nbsp;Aikaterini Syrigou,&nbsp;Maria Gangadi,&nbsp;Antonios Christopoulos,&nbsp;Dimosthenis Papapetrou,&nbsp;Fotios Psarros,&nbsp;Konstantinos Gourgoulianis,&nbsp;Eleni Tzortzaki,&nbsp;Stylianos K. Vittorakis,&nbsp;Ioannis Paraskevopoulos,&nbsp;Ilias Papanikolaou,&nbsp;Georgios Krommidas,&nbsp;Dimitrios Latsios,&nbsp;Nikolaos Tzanakis,&nbsp;Miltiadis Markatos,&nbsp;Angeliki Damianaki,&nbsp;Argyrios Manikas,&nbsp;Alexia Chatzipetrou,&nbsp;Dimitrios Vourdas,&nbsp;Ioanna Tsiouprou,&nbsp;Christina Papista,&nbsp;Marina Bartsakoulia,&nbsp;Nikolas Mathioudakis,&nbsp;Petros Galanakis,&nbsp;Petros Bakakos","doi":"10.1002/clt2.70035","DOIUrl":"10.1002/clt2.70035","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Data on type 2 (T2)-low severe asthma (SA) frequency is scarce, resulting in an undefined unmet therapeutic need in this patient population. Our objective was to assess the frequency and characterize the profile and burden of T2-low SA in Greece.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>PHOLLOW was a cross-sectional study of adult SA patients. Based on a novel proposed classification system, patients were classified as T2-low if blood eosinophil count (BEC; cells/μL) was &lt;150, fractional exhaled nitric oxide (FeNO) &lt; 25 ppb and any allergy status or BEC &lt; 150/FeNO &lt; 50 ppb/no allergy or BEC &lt; 300/FeNO &lt; 25 ppb/no allergy. For patients receiving biologics and/or oral corticosteroids, only those with BEC &lt; 150/FeNO &lt; 25 ppb/no allergy/no response to therapy were classified as T2-low. Secondary outcome measures were: Asthma Control Test (ACT^TM), Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ), hospital anxiety and depression scale (HADS), and Work Productivity and Activity Impairment:Respiratory Symptoms (WPAI:RS) questionnaire.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>From 22-Mar-2022 to 15-Mar-2023, 602 eligible SA patients were enrolled. The frequency of T2-low asthma was 20.1%. Of those, 71.1% had experienced ≥1 clinically significant exacerbations in the past year, 62.8% had ACT score &lt;20 (uncontrolled asthma), and 22.3% were biologic-treated. Mini-AQLQ score was &lt;6 (impairment) in 79.5% of patients, HADS-total score was ≥15 (clinically significant emotional distress) in 43.8%, while median percent activity impairment and work productivity loss were 30.0 for both domains. Clinical and patient-reported outcomes were worse among patients with ACT-defined uncontrolled asthma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>One-fifth of SA patients present with a T2-low endotype. These patients frequently have uncontrolled disease and experience impairments in their quality of life, emotions and work ability.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 2","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11779522/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of revision endoscopic sinus surgery in Finnish patients with chronic rhinosinusitis with nasal polyps","authors":"Sanna Toppila-Salmi,&nbsp;Annina Lyly,&nbsp;Johanna Simin,&nbsp;Juhani Aakko,&nbsp;Helga Haugom Olsen,&nbsp;Lauri Lehtimäki","doi":"10.1002/clt2.70032","DOIUrl":"10.1002/clt2.70032","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Although patients with chronic rhinosinusitis with nasal polyps (CRSwNP) may benefit from endoscopic sinus surgery (ESS), some patients will experience polyp recurrence, adding to the overall disease burden of CRSwNP. We aimed to investigate predictors of revision ESS in patients with CRSwNP.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A nationwide population-based study including all adults diagnosed with CRSwNP who had surgical procedure codes for ESS (<i>N</i> = 3506), followed up between January 2012 and December 2019. Logistic regression models provided adjusted odds ratios (OR) with 95% confidence intervals (CIs) for the odds of revision surgery within one and 3 years post-index surgery.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>559 (15.9%) of the patients had at least one revision surgery during the follow-up. Median time to revision of ESS was 425 days (interquartile range: 213–898). Baseline asthma (OR = 1.58, 95% CI 1.17–2.12) and antibiotic use (OR = 1.61, 95% CI 1.27–2.04) were associated with higher odds of revision ESS, particularly within 3 years post-index surgery, whereas Increasing age was inversely associated with the odds of ESS revision (OR = 0.82, 95% CI 0.76–0.88). The highest odds of revision ESS were observed within 3 years post-index surgery in patients who had undergone extensive surgery at index (OR = 14.13, 95% CI 3.41–95.64) compared with those who had undergone limited surgery. OCS use was frequent among CRSwNP patients, with a higher cumulative dose in patients undergoing multiple ESS revisions (63%, <i>n</i> = 97, median daily dose 3.29 mg, IQR: 1.64–3.70) compared with patients without revisions (49%, <i>n</i> = 1361 and 1.64 mg, IQR: 1.64–3.29, respectively. <i>p</i>-value &lt;0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>A small proportion of CRSwNP patients require revision ESS with associated high cumulative OCS doses, highlighting the need for additional therapies to achieve disease control and reduce the corticosteroid burden. A few simple baseline characteristics can predict the need for recurrent surgery among the patients with CRSwNP.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 2","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11779534/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}